Bristol Myers’ BMY legacy portfolio comprises Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane. Revenues for the Legacy ...

Bristol Myers and Celgene are being sued in an antitrust suit, alleging they used fraud, sham litigation, and reverse ...

Incyte INCY announced that the FDA has approved its humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, ...

Fourth-quarter Revlimid sales of $2.26 billion topped Wall Street estimates of $1.89 billion, according to Refinitiv data. Sign up here. The company expects Revlimid sales to fall to $6.5 billion ...

Shares of this biotech giant have lost 16.3% year to date compared with the industry’s decline of 2.7%. The stock has also ...

Revlimid (lenalidomide) is a brand-name oral capsule prescribed for certain types of myeloma, lymphoma, and anemia. As with other drugs, Revlimid can cause side effects, such as skin rash and ...

His investigation into the discovery and marketing of the drug Revlimid revealed strategies employed by pharmaceutical companies to ward off competition, and keep prices of their medications high.

Maintenance treatment with Darzalex (daratumumab) and Revlimid (lenalidomide) resulted in superior outcomes compared with standard-of-care Revlimid alone following autologous stem cell transplantation ...

When Celgene Corp. first started marketing the drug Revlimid to treat multiple myeloma in 2006, the price was $6,195 for 21 capsules, a month's supply. By the time David Mitchell started taking ...

One of the most important questions in myeloma these days is how long you should continue maintenance for. I mean, I'm gonna say five studies and a meta-analysis showed that maintenance Revlimid ...

Shares of Dr Reddy's Laboratories decreased by 2 per cent to Rs 1,317 in morning trading, following Citi Research's decision ...

The prescribed dosage for Revlimid (lenalidomide) may vary depending on a person’s individual treatment plan. Other factors, including your specific diagnosis and medical history, may affect ...